On May 15, 2025, Senseonics Holdings, Inc. entered into a $25 million securities purchase agreement with Abbott Laboratories, allowing Abbott to acquire shares representing 4.99% of the company following a public offering. The agreement includes terms on information rights and an exclusive negotiation period for strategic transactions.